Mochtar Riady Institute for Nanotechnology.

Mochtar Riady Institute for Nanotechnology (MRIN) was founded in 2006 as part of the Lippo Health and Medical Program, consisting of UPH Faculty of Medicine, UPH Biotechnology, Siloam Hospitals and Mochtar Riady Comprehensive Cancer Center (MRCCC).

MRIN responded to the global pandemic by doing research on Covid-19. Until today, MRIN is known to be the only private research institute in Indonesia to participate in sending genomes to GISAID, with a total of 17 sequences in May 2020 and January 2021.

To know more about MRIN, visit MRIN website



  • To become an internationally recognized research center in the field of nanomedicines focusing on oncology.
  • To improve the nation’s quality and competency in the field of nanomedicines through quality education and scientific discovery.
  • To foster research and education in the field on nanomedicines through interdisciplinary research partnerships and collaborations


  • To conduct innovative research on cancer prevention and new understandings of the cause, early diagnosis, control and cure of cancer.

Latest Update.

RNA/DNA Isolation Lab.

This laboratory is a place to extract nucleic acids (DNA/RNA) from biological sources (such as blood / tissue). This lab. is supported with Biological Safety Cabinet level 2, centrifuge with various capacities, and sonicator.

SNP Lab.

Single Nucleotide Polymorphism (SNP) Laboratory provides expertise in DNA and molecular genetic experiment that conducts research on health and disease at the population level. This lab is supported by Genetic Analyzer instrument, PCR machine, DNA electrophoresis and its molecular imaging system, and also Spectrophotometry tools. Biospecimen such as DNA, RNA, blood, tissue and urine were kept in this room at two low temperature (minus 20 degree) and four ultra low temperature (minus 80 degree) freezer.

Pathology Lab.

Pathology Laboratory in MRIN provides tissue processing tools to support histology or histopathology diagnostic such as ; Tissue Processor and Tissue Parafin Embedding Station. Biosafety Cabinet class 2 is also provided as personal protection in this lab. for tissue preparation or staining procedure.

Genomic Lab.

The Genomic Laboratory focuses on genome-wide and DNA analysis to support cancer research. Some lab. instruments available in Genomic Lab Laminar flow cabinet, The thermocycler/PCR machine, Electrophoresis apparatus, and many more.

Flow Cytometry Lab.

Flow Cytometry is a laboratory method used to detect, identify, and count specific cells. This method can also identify particular components within cells.

Cell Culture Lab.

Cell culture laboratory has a capacity for routine mammalian cell culture (maintaining and sub-culturing) and for other experiments in an artificially controlled environment. It has two Biosafety Cabinet (BSC) level 2, Incubator CO2, Freezer (-80 and -20), Microscope, Cell Counter and other equipment that supports all the experiments.

Proteomic Lab.

The Proteomics Laboratory at MRIN is equipped with state of the art instrument, such as Western Blot, HPLC, Microplate Reader, Freeze dryer and Akta Purifier. With these instruments, MRIN team are able to conduct and provide various proteomics analysis such as separation, identification, characterization and quantification of proteins expressed in biological samples.

Disposal Treatment Room.

This room is equipped with two units of autoclaved machine for waste and clean sterilizing. The exhaust fan attached at the ceilling supports air flow and eliminates heat from the room. Ice-breaker machine is also provided to support MRIN's laboratory work and high temperature incubator (60 degrees).

Preparation Room.

Preparation Lab is the place to make all the chemical buffers and reagents needed in the experiments. The Lab. is provided with equipment to support the work such as; pH Meter, Scale, Analytical Scale, and ELGA Water Purifier.

Microscope Room.

Microscopes is one of the supporting research equipment in Mochtar Riady Institute. Microsopes are use to support cancer research (cell culture, Histology, in situ hybridization, and immunohistochemitry).


Prof. dr. Irawan Yusuf, Ph.D.

President of Mochtar Riady Institute for Nanotechnology
Prof. dr. Irawan Yusuf, Ph.D after his undergraduate from medical doctor from Hasanuddin University. In 1992, he continued the Post Doctoral at the School of Medicine, University of Hiroshima in the field of molecular and cellular cardiac electrophysiology. He has been a Lecture at Physiology Department, Faculty of Medicine, Universitas Hasanuddin, Makasar since 1986. He was appointed as a Vice Dean in 2002 and continued his career as a Dean from 2006 to 2014. His university promoted him as Professor of Physiology in 2005 He joined as a Senior Researcher at Eijkman Institute from 1995 to 2002, He had been invited as external examiner for Ph.D of Leiden University in 2007, Utrecht University in 2009, Amsterdam University in 2013, and as a Visiting Professor at Kyoto University, Japan in 2015. He was honoured with the best of Head of Study Program from Ministry of Research and Technology, Republic of Indonesia in 2009 and received Satya Lencana Karya 20 years from the Government of Republic Indonesia in 2010. He is also received Juned Pusponegro award from Indonesian Medical Association in 2012 and Ahmad Bakrie Award for Medical Category in 2013 He is appointed as Chair of Steering Committee Novartis Eijkman Hasanuddin Clinical Research Initiative which is focusing research in tuberculosis and dengue fever. He was also appointed as Chair of Ethic Committee at Mochtar Riady Institute for Nanotechnology, Member of National Research Board, National Bioethics Commission and Vice Chair of National Ethics Commission on Health Research. From 2007 to 2009 he was a Chairman of Indonesian Medical Association, and from 2009 – 2012 he was a Chairman of Indonesian Medical Colloqium. From 2008 up to know he has been involving in the Indonesian Academy of Science.

Dr. rer. nat. Ivet Suriapranata

Principal Investigator
Received her PhD degree in Biochemistry from the University of Stuttgart, Germany. Prior to joining the MRIN, she was Postdoctoral Researcher in the Division of Biological Sciences, University of California, San Diego, USA. Her research interest is Single Nucleotide Polymorphism in association with cancer development and progression.

Professor Wahyuni Lukita Atmodjo M.D., Ph.D.

Principal Investigator
Received her Ph. D degree in Medical Science from Kobe University, Kobe, Japan. She accomplished her Postdoctoral Research at Tokyo Medical and Dental University, Tokyo, Japan. She was as a research fellow in the College of Medicine, University of Arizona sponsored by Educational Commission for Foreign Medical Graduate (ECFMG), Washington DC, USA. Her main research interests are Morphological and Micro Vascular Responses due to Paracrine and Autocrine Relationship among Liver Sinusoidal Cells in the Inflammatory Process towards Cirrhosis.

Dr. rer. nat. Bustanur Rosidi

Principal Investigator
Dr.Rernat Bustanur Rosidi studied Biochemistry at Leibniz University of Hannover, Germany. After completing his PhD he joined the research group of Prof. Dr. George Iliakis at Institute for Medical Radiation Biology, University Duisburg-Essen’s Medical School in Essen Germany,as Post Doc. He then moved to Malaysia and worked as senior lecturer at University Technology Malaysia in Johor Bahru, before joined MRIN in July 2012. His research area of interest is cancer chemoprevention with focus on colorectal cancer.

Dr. John Eu-Li Wong, MBBS, FAMS, FRCP, FACP

Scientific Advisory Board Members
Dr. John Wong is Dean of the Yong Loo Lin School of Medicine at the National University of Singapore (NUS), Deputy Chief Executive of the National University Health System (NUHS) and Director of the National University Cancer Institute, Singapore (NCIS). A medical oncologist-haematologist, Dr. Wong obtained his MBBS from NUS and did his residency and fellowship at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center. With research interests in the development of new drugs and treatment strategies, and differences between Asian and Caucasian cancers, Dr. Wong jointly founded the Cancer Therapeutics Research Group (CTRG), a multi-national consortium of nine institutions, and has served on the American Society of Clinical Oncology International Affairs Committee. He has been actively involved in the development of the biomedical sciences as a key pillar of Singapore’s economy, as well as the introduction of Singapore’s first academic health system, linking the National University Hospital and the National University of Singapore’s medical, dental, and nursing schools under one unified governance. Dr. Wong has initiated collaborations with leading institutions in Europe, Asia, and the U.S. He has also been involved in the expansion of the Association of Academic Health Centers into AAHC International. He serves on the International Coordinating Committee of AAHC International and organized the AAHC Inaugural Asia Pacific Meeting in Singapore in February 2009. He is a frequent invited speaker on academic medicine at international meetings such as the AAHC International Forum, the World Health Summit, and the Annual World Health Care Congress Europe.

Prof. Esther H. Chang, MD, Ph.D.

Scientific Advisory Board Members
Professor Esther H. Chang is a member of the Departments of Oncology and Otolaryngology at the Lombardi Cancer Center, Georgetown University Medical Center. Before joining Georgetown University, Dr. Chang held positions in the National Cancer Institute, as a professor in the Department of Surgery at Stanford University, and as a professor in the Departments of Pathology and Surgery at the Uniformed Services University of the Health Sciences. Dr. Chang has been a pioneer and major contributor to understanding genetic influences on both the development and suppression of cancerous tumors, as well as to understanding the tumor’s resistance to radio/chemotherapy. She was the first to identify human versions of a mouse viral oncogene and to demonstrate the role of these “ras oncogenes” in causing cancer. Her research group also was the first to demonstrate, simultaneously with another, that a mutated p53 gene inherited in a cancer-prone family plays a role in the early stages of cancer development. Recently, her research on the application of nanotechnology to cancer therapy, diagnosis and prevention was recognized in Science News Magazine as among the most promising efforts in the field. Her group also has been evaluating the combination of tumor-targeted gene therapy and more conventional radiotherapy or chemotherapy for treatment of cancers. Dr. Chang has served as a member of a number of scientific advisory boards for the National Cancer Institute, NASA, the US Military Cancer Institute, and the Department of Energy. Her scientific findings have been published in prominent journals including Nature, Science, and Cell, as well as many other leading journals. Dr. Chang also has dedicated much time to the education of graduate and medical students, and has held peer reviewed grants from the NIH for more than 20 years, without interruption.